Category: Featured

This report examines the development of uncrewed underwater vehicles (UUVs) in Australia and India and the case for bilateral cooperation in the undersea domain. It argues that the two national ecosystems are complementary rather than competitive, and that a phased, capability-driven partnership that begins with benign and civil applications is more likely to endure than early collaboration in sensitive undersea warfare technologies.

This essay examines why the India-Bangladesh relationship, which New Delhi regarded as stable and deeply aligned until August 2024, broke down so completely and so quickly. Drawing on Brantly Womack’s […]

This report examines Australia–India anti-submarine warfare (ASW) cooperation within an increasingly contested Indo-Pacific undersea environment. It argues that meaningful, campaign-level cooperation is both achievable and strategically valuable without requiring alliance-style integration or the sharing of highly sensitive sensor architectures.  Cooperation is best structured around aligned doctrine, greater intelligence sharing, and routine operational coordination that builds the enduring relationships between the two operational-level headquarters.

India has built foreign-designed weapons under license for six decades without acquiring design authority. This report explains why: procurement treats technology transfer as a contractual deliverable, but absorption cannot be contracted for. It sets out a ladder of technological depth and a five-stage chain, then scores four programs against them.

This report analyzes the structural asymmetry between the Indian and South Korean shipbuilding industries and the case for converting it into a durable industrial partnership. Indian scale, demand, and demography align with Korean technology, production systems, and institutional depth, and the complementarity is strong enough to support a relationship that goes beyond a commercial transaction.

This report makes the case for deepening India-Canada trade in finished pharmaceutical products and for institutionalizing it under the CEPA negotiations now targeted for conclusion by the end of 2026.